Assertio Therapeutics, Inc. (ASRT)
Stock Price:
$0.672 USD
-0.040 (-5.64%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.675 +0.003 (0.45%) Oct 21, 5:33 PM
Key Info
| Market Cap |
71.99M |
| Revenue (ttm) |
155.91M |
| Net Income (ttm) |
-182.56M |
| Shares Out |
107.12M |
| EPS (ttm) |
-2.19 |
| PE Ratio |
n/a |
| Forward PE |
5.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$0.672 |
| Previous Close |
$0.712 |
| Change ($) |
-0.040 |
| Change (%) |
-5.64% |
| Day's Open |
0.716 |
| Day's Range |
0.663 - 0.716 |
| Day's Volume |
434,548 |
| 52-Week Range |
0.550 - 1.710 |
More Stats
| Market Cap |
71.99M |
| Enterprise Value |
111.79M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
107.12M |
| Float |
92.06M |
| EPS (basic) |
-2.43 |
| EPS (diluted) |
-2.19 |
| FCF / Share |
-0.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.08M |
| Short Ratio |
2.12 |
| Short % of Float |
1.17% |
| Beta |
2.02 |
| PE Ratio |
n/a |
| Forward PE |
5.48 |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.46 |
| PB Ratio |
0.90 |
| Revenue |
155.91M |
| Operating Income |
-243.50M |
| Net Income |
-182.56M |
| Free Cash Flow |
-4.26M |
| Net Cash |
-39.81M |
| Net Cash / Share |
-0.37 |
| Gross Margin |
141.10% |
| Operating Margin |
-156.18% |
| Profit Margin |
-117.10% |
| FCF Margin |
-2.73% |
| ROA |
-4.28% |
| ROE |
-129.29% |
| ROIC |
-109.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$2.48*
(269.05% upside)
Low
1.45
Current: $0.672
High
3.50
Target: 2.48
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 230 | 312 | 381 | 456 | 343 | 390 | 134 | 90.82 | 133 | 80.76 |
| Revenue Growth | -26.39% | -18.11% | -16.49% | 33.02% | -12.2% | 190.87% | 47.78% | -31.7% | 64.64% | - |
| Gross Profit | 220 | 293 | 308 | 368 | 275 | 375 | 127 | 84.78 | 127 | 72.67 |
| Operating Income | -194 | 43.66 | -42.18 | 24.51 | -50.40 | 237 | 9.32 | -30.35 | 70.70 | 3.63 |
| Net Income | -217 | 36.91 | -102 | -88.72 | -75.74 | 132 | 43.31 | -29.78 | 70.73 | 3.90 |
| Shares Outstanding | 70.72 | 63.79 | 62.70 | 61.30 | 60.12 | 58.29 | 56.74 | 55.89 | 54.56 | 52.53 |
| Earnings Per Share | -3.07 | 0.57 | -1.63 | -1.45 | -1.26 | 2.05 | 0.75 | -0.53 | 1.26 | 0.07 |
| EPS Growth | - | - | - | - | - | 173.33% | - | - | 1700% | - |
| Operating Cash Flow | 90.48 | 72.50 | 62.17 | 71.26 | 152 | -55.92 | 9.75 | -30.99 | 57.65 | -2.38 |
| Capital Expenditures | -1.48 | -5.36 | -0.39 | -2.86 | -1.72 | -0.60 | -1.81 | -6.88 | -0.70 | -0.18 |
| Free Cash Flow | 88.99 | 67.14 | 61.78 | 68.40 | 151 | -56.52 | 7.94 | -37.87 | 56.95 | -2.56 |
| Cash & Equivalents | 42.11 | 111 | 128 | 177 | 210 | 559 | 272 | 66.81 | 86.15 | 70.35 |
| Total Debt | 351 | 566 | 627 | 719 | 800 | 230 | - | - | - | 2.17 |
| Net Cash / Debt | -309 | -455 | -499 | -541 | -591 | 330 | 272 | 66.81 | 86.15 | 68.18 |
| Assets | 527 | 933 | 1,039 | 1,225 | 1,357 | 711 | 509 | 142 | 164 | 87.03 |
| Liabilities | 469 | 713 | 869 | 975 | 1,042 | 347 | 371 | 57.72 | 58.45 | 63.93 |
| Book Value | 57.96 | 220 | 170 | 251 | 315 | 364 | 137 | 83.94 | 106 | 23.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Assertio Therapeutics, Inc. |
| Country |
United States |
| Employees |
125 |
| CEO |
Todd N. Smith |
Stock Information
| Ticker Symbol |
ASRT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: ASRT |
| IPO Date |
November 5, 1997 |
Description
Assertio Holdings operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version of tapentadol for the management of moderate to severe acute pain. The company has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.